Dr Capucine Baldini speaks to ecancer about the updates in medical oncology at SIOG 2024.

The conference highlights updates in medical oncology, particularly for GU and lung cancers, and introduces new treatment options like antibody-drug conjugates (ADCs) and T-cell engagers.

ADCs are now approved for first-line treatment alongside immune checkpoint inhibitors, though data on older patients is lacking.

The need for geriatric scores in trials is emphasised, and a study on radiation therapy for breast cancer suggests new standards of care.

Patient involvement in trial design is also discussed.